LoQus23 Therapeutics announces £35 million financing to advance a new drug aimed at inhibiting somatic expansion in Huntington’s Disease

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy type 1 and similar triplet repeat expansion diseases, today announces Czytaj dalej...

Pridopidyna firmy Prilenia stosowana w chorobie Huntingtona dopuszczona do europejskiego przeglądu pozwoleń na dopuszczenie do obrotu

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Czytaj dalej...

IROS, Prilenia i International Huntington's Disease Association współpracują nad pierwszym w historii badaniem choroby Huntingtona (HD) w regionie MENA.

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial Czytaj dalej...

uniQure ogłasza pozytywną aktualizację danych okresowych wykazujących spowolnienie progresji choroby w badaniach fazy I/II AMT-130 dla HD

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe Czytaj dalej...

Wave Life Sciences ogłasza pozytywne wyniki badania fazy 1b/2a SELECT-HD, w którym po raz pierwszy wykazano kliniczne działanie obniżające stężenie zmutowanej huntingtyny w chorobie Huntingtona.

Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) protein and preserves healthy, wild-type huntingtin (wtHTT) protein for individuals Czytaj dalej...

pl_PLPolish
Przejdź do treści